2月23日 - ** 药物开发商Gossamer Bio GOSS.O股价盘前下跌67%至69美分
** 该公司称其治疗一种肺部疾病的实验性药物seralutinib未能在一项后期研究中达到主要目标 (link)。
** 该公司称，在24周时，服用seralutinib的患者步行距离中位数提高了28.2米，而服用安慰剂的患者步行距离中位数提高了13.5米。
** 补充说，但结果没有达到预设的统计阈值
** 该公司正在肺动脉高压患者中测试这种药物，肺动脉高压是指肺动脉中的高血压导致肺动脉狭窄和僵硬。
** 2025年，GOSS股价上涨了242%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.